| The hepatitis C cascade of care: identifying priorities to improve clinical outcomes BP Linas, DM Barter, JA Leff, SA Assoumou, JA Salomon, MC Weinstein, ... PloS one 9 (5), e97317, 2014 | 147 | 2014 |
| The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection BP Linas, DM Barter, JR Morgan, MT Pho, JA Leff, BR Schackman, ... Annals of internal medicine 162 (9), 619-629, 2015 | 125 | 2015 |
| Long COVID and health inequities: the role of primary care Z Berger, VA De Jesus, SA Assoumou, T Greenhalgh The Milbank Quarterly 99 (2), 519, 2021 | 100 | 2021 |
| Cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings SA Assoumou, A Tasillo, JA Leff, BR Schackman, ML Drainoni, ... Clinical Infectious Diseases 66 (3), 376-384, 2018 | 86 | 2018 |
| Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge P Sinha, A Mostaghim, CG Bielick, A McLaughlin, DH Hamer, LM Wetzler, ... International Journal of Infectious Diseases 99, 28-33, 2020 | 81 | 2020 |
| Projected estimates of opioid mortality after community-level interventions BP Linas, A Savinkina, R Madushani, J Wang, GE Yazdi, A Chatterjee, ... JAMA network open 4 (2), e2037259-e2037259, 2021 | 50 | 2021 |
| Cost-effectiveness and budgetary impact of hepatitis C virus testing, treatment, and linkage to care in US prisons SA Assoumou, A Tasillo, C Vellozzi, G Eftekhari Yazdi, J Wang, S Nolen, ... Clinical Infectious Diseases 70 (7), 1388-1396, 2020 | 38 | 2020 |
| Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort JR Morgan, AY Walley, SM Murphy, A Chatterjee, SE Hadland, J Barocas, ... Drug and alcohol dependence 225, 108764, 2021 | 28 | 2021 |
| Cost-effectiveness of surveillance strategies after treatment for high-grade anal dysplasia in high-risk patients SA Assoumou, KH Mayer, LA Panther, BP Linas, JJ Kim Sexually transmitted diseases 40 (4), 298-303, 2013 | 25 | 2013 |
| The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients BP Linas, DM Barter, JA Leff, M DiLorenzo, BR Schackman, ... Aids 28 (3), 365-376, 2014 | 22 | 2014 |
| Relationship between hepatitis C clinical testing site and linkage to care SA Assoumou, W Huang, CR Horsburgh Jr, ML Drainoni, BP Linas Open forum infectious diseases 1 (1), ofu009, 2014 | 21 | 2014 |
| Addressing inequities in SARS-CoV-2 vaccine uptake: the Boston Medical Center health system experience SA Assoumou, A Peterson, E Ginman, T James, CM Pierre, S Hamilton, ... Annals of Internal Medicine 175 (6), 879-884, 2022 | 19 | 2022 |
| Cost effectiveness and cost containment in the era of interferon-free therapies to treat hepatitis C virus genotype 1 BP Linas, JR Morgan, MT Pho, JA Leff, BR Schackman, CR Horsburgh, ... Open forum infectious diseases 4 (1), ofw266, 2017 | 19 | 2017 |
| HCV testing and treatment in a national sample of US federally qualified health centers during the opioid epidemic SA Assoumou, J Wang, S Nolen, G Eftekhari Yazdi, KH Mayer, J Puro, ... Journal of general internal medicine 35, 1477-1483, 2020 | 17 | 2020 |
| Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs E Childs, SA Assoumou, KB Biello, DL Biancarelli, ML Drainoni, A Edeza, ... Harm reduction journal 16, 1-10, 2019 | 17 | 2019 |
| Sexually transmitted and blood-borne infections among patients presenting to a low-barrier substance use disorder medication clinic L Harvey, JL Taylor, SA Assoumou, J Kehoe, EM Schechter-Perkins, ... Journal of addiction medicine 15 (6), 461-467, 2021 | 16 | 2021 |
| Hepatitis C virus antibody testing among 13-to 21-year-olds in a large sample of US federally qualified health centers RL Epstein, J Wang, L Hagan, KH Mayer, J Puro, BP Linas, SA Assoumou JAMA 322 (22), 2245-2248, 2019 | 15 | 2019 |
| HIV pre-exposure prophylaxis and buprenorphine at a drug detoxification center during the opioid epidemic: opportunities and challenges SA Assoumou, SM Paniagua, P Gonzalez, J Wang, CG Beckwith, ... AIDS and Behavior 25, 2591-2598, 2021 | 14 | 2021 |
| Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: a qualitative study SA Assoumou, CR Sian, CM Gebel, BP Linas, JH Samet, JA Bernstein Drug and alcohol dependence 220, 108526, 2021 | 13 | 2021 |
| Eighteen‐to 30‐year‐olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission KL Young, W Huang, CR Horsburgh, BP Linas, SA Assoumou Journal of viral hepatitis 23 (4), 274-281, 2016 | 13 | 2016 |
